AUS: (617) 38560661 | US: (855) 950-4567 | E-mail:

Download our White Paper

for the latest clinical research and market information on bladder health


Urox® is designed to effectively assist bladder control symptoms that affect both men and women.

Learn More


Prostate and Bladder combined for comprehensive effectiveness

Learn More


Nocturnal enuresis or bedwetting affects many children (over age 5) who have achieved daytime dryness with potty-training.

Learn More


A high standard of manufacture with strict quality control, safety and efficacy adopted by Australia well before most other countries, combined with the pristine Australian environment and “out-back” entrepreneurial attitude shaped the prototype Urox® formula, developed in Australia the late 1990s and launched in 1999.

Patented Urox® has been proven effective in clinical practice and six clinical trials, and once again shown statistically significant results in a recently published clinical study (January 2018) that no other herbal remedy has achieved to date:

  • 23% of participants fully continent by 2 months
  • Total average day frequency returned to normal
  • 60% reduction in urinary urgency
  • Halving of nocturia
  • 60% average reduction in urinary incontinence (both stress and urge)
  • 75% of Urox users reduced their pad usage to one or less per day
  • 84% Urox users felt the treatment had benefitted them
  • All responses in active group showed improvement in Quality of Life
  • Results are seen in as little as 2 weeks
  • No significant adverse effects or known drug interactions
Urox® is manufactured according to PIC/S Guide to Good Manufacturing Practice for Medicinal Products and available as finished bottled product, bulk capsules and powdered blend or incorporated into custom formulations for highly regarded supplement brands, private label retailers and contract manufacturers around the globe.

As Seipel Group progressed, so has our family of products.  Over the years, formulations extending the product line have been developed to target complementary symptoms that affect men and children.